Compare Amylx Pharmaceuticals Inc (AMLX) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs ING Groep NV — how do they compare? Amylx Pharmaceuticals Inc trades at $17.28 (market cap $1.98B), while ING Groep NV trades at $32.29 (market cap $92.53B). The key difference: ING Groep NV is far larger — about 46.7× Amylx Pharmaceuticals Inc's market cap, and ING Groep NV pays a 3.91% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | ING | |
|---|---|---|
Market Cap | $1.98B | $92.53B |
Sector | Health | Financials |
52-Week High | $18.70 | $32.96 |
52-Week Low | $7.64 | $22.45 |
Enterprise Value | $1.70B | — |
Dividend Yield | — | 3.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
ING trades at $32.39, down 0.34% today, with a bullish technical outlook supported by moving averages. The company maintains strong profitability with a 27.84% net income margin and has beaten earnings expectations for three consecutive quarters. Recent developments include the launch of a global subscription banking model and a $0.88 dividend payment scheduled for May 2026.
The stock presents a compelling value opportunity with a P/E of 12.99 and strong analyst support (62.5% buy ratings). However, negative operating cash flow trends and exposure to European banking sector volatility represent key risks. Upside potential exists from continued earnings outperformance and strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
